---
title: "Aptevo Therapeutics posts investor presentation on multispecific immunotherapies for cancer, led by mipletamig in AML"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290859040.md"
description: "Aptevo Therapeutics released an investor presentation highlighting mipletamig for frontline AML, reporting 81% CR/CRi rates. The company provided a safety update from the RAINIER study and outlined development timelines targeting Phase 2 initiation in 2027. Additionally, Aptevo detailed a 50/50 collaboration with Niowave for radiopharmaceutical programs and emphasized pipeline candidates like APVO451 for solid tumors."
datetime: "2026-06-25T16:25:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290859040.md)
  - [en](https://longbridge.com/en/news/290859040.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290859040.md)
generator: "portal-rs"
---

# Aptevo Therapeutics posts investor presentation on multispecific immunotherapies for cancer, led by mipletamig in AML

-   Aptevo highlighted mipletamig in frontline AML with venetoclax-azacitidine, citing 81% CR/CRi and 65% CR in 31 patients. \* Safety update showed no cytokine release syndrome through Cohort 5 in the RAINIER dose-optimization study; more than 120 patients treated across trials. \* Development timeline targets recommended Phase 2 dose selection by year-end 2026; Phase 2 start in 1H27; first patient dosing in 2H27. \* Niowave collaboration set as a 50⁄50 effort to develop up to three radiopharmaceutical programs, starting with a Nectin-4/actinium-225 target. \* Pipeline emphasis included trispecific solid-tumor candidates such as APVO451; development candidate selection targeted by year-end 2026; IND-enabling studies in 1Q27. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [APVO.US](https://longbridge.com/en/quote/APVO.US.md)

## Related News & Research

- [Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results | APVO Stock News](https://longbridge.com/en/news/295932565.md)
- [Aptevo wins $1.5 million CARE Fund grant for APVO451 IND-enabling work](https://longbridge.com/en/news/295932679.md)
- [Moleculin highlights interim data from pivotal MIRACLE Phase 2/3 Annamycin trial in relapsed/refractory AML](https://longbridge.com/en/news/297191000.md)
- [Biovica signs master services agreement with US biotech subsidiary for cancer drug development testing services](https://longbridge.com/en/news/297162314.md)
- [Filament Health ships psilocybin candidate PEX010 for University of Washington Phase 2a cancer anxiety, depression trial](https://longbridge.com/en/news/296906129.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**